5Nathan DM, Buse JB, Davldson MB,et al. Medical management of hypcr- glyemia in type 2 diabetes AND a consensus algorithm for the initiation and adjustment of therapy[J]. Diabetes Care,2009;32 (5):58.
7Wiesli P, Krayenbiihl P, Uthoff H, et al. Omitting breakfast and hmch af- ter injection of different long-acting insulin prepa-rations at bedtime: a prospective study in patients with type 2 diabetes [J]. Diabetologia, 2009 ;52 : 1816-9.
7Riddle MC, Rosenstock J, Gerich J. The treat to target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 2003,26:3080-3086.
8Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care, 2005,28:254-259.
9Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care, 2003,26:881-885.
10Rizzo MR, Barbieri M, Grella R, et al. Repaglinide is more efficient than glimepiride on insulin secretion and postprandial glucose excursions in patients with type 2 diabetes. A short term study. Diabetes Metab, 2004,30:81-89.
5Bryant Ginelle A, McDanel Deanna L, Homer Kathleen E, et al.. Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir [ J ] Pharmaco- therapy,2013 ,2( 1 ) :331-332.
6Marie J, Mette D, Vega MD. Insulin analogues dosing and costs- comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients. [ J ]. BMC Endocrine Disor- ders .2012.12(2) :356-357.
7Duran C, Tuncel E, Ersoy C, et al. The investigation of theefficacy of insulin glargine on glycemic control when combinedwith either repaglinide or acarbose in obese Type 2 diabeticpatients[ J]. J Endocrinol Invest,2009,32( 1) :69 -73.
8Derosa G,Salvadeo SA, Angelo A, et al. Metabolic effect ofrepaglinide or acarbose when added to a double oral antidiabetictreatment with sulphonylureas and metformin: a double-blind,cross-over,clinical trial[ J]. Curr Med Res Opin,2009,25 ( 3 ):607 -615.
